3D Global Biotech

What 3D Global Biotech does

3D Global Biotech is a Taiwan-based, privately held biotechnology company founded in 2014 and headquartered in Taipei. Per its firmographic profile, it develops products in three biomedical categories: artificial bone grafting materials, biotechnology inks, and ophthalmic products. The company operates at a small scale, with a headcount band of 11–50 employees, indicating an early-to-growth stage organization likely balancing R&D, manufacturing process development, and early commercial activity rather than a scaled commercial enterprise. Its product surface spans regenerative medicine (bone graft substitutes), bio-fabrication inputs (biotech inks, suggesting possible use in 3D bioprinting workflows), and ophthalmology — a portfolio breadth that points to a biomaterials and tissue-engineering orientation rather than a single-asset drug developer.

The underlying technology and platform architecture are not described in the available sources beyond a generic contextual note referencing alginate-gelatin hydrogel research and tissue regeneration. There is no documentation of proprietary processes, patented formulations, manufacturing methods, or regulatory clearances in the input data. The company's website (3dglobalbiotech.com.tw) returns only a verification/loading placeholder, and no press releases, investor materials, partnership announcements, or product specifications were surfaced in the supplied sources.

The business model cannot be characterized with confidence from the available data: no pricing model, no customer list, no distribution channel, no disclosed revenue, and no funding history are present. Given the product categories (medical-grade biomaterials, likely medical device or biologic regulation), plausible revenue mechanics would include B2B sales to hospitals/clinics, OEM/licensing of bio-inks, and distributor arrangements, but none of these are confirmed in the sources. A financial table included with the inputs shows figures in the trillions that are inconsistent with a private Taiwanese firm of this size and appear to be misattributed; they are not used here. Overall, the company profile is best characterized as a small, product-diversified Taiwanese biomaterials developer with limited publicly verifiable operating detail.

Name

3D Global Biotech

Website

https://3dglobalbiotech.com.tw

Company type

Private

Founded year

2014

Headcount range

11–50 employees

Short description

3D Global Biotech is a privately held Taipei-based biotechnology company founded in 2014 that develops artificial bone grafting materials, biotechnology inks, and ophthalmic products, operating with a small team of 11–50 employees.

Ownership category

akta.pro rank

Product category

Tissue Engineering Biomaterials

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

3D Bioprinting & Biofabrication (HLAAAGAC)

akta.pro secondary industries

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)

Keywords

• Artificial bone grafting
• Biotechnology inks
• Ophthalmic products
• Tissue regeneration
• Biomedical materials

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations

Core offering

3D Global Biotech develops and manufactures biomedical products including artificial bone grafting materials, biotechnology inks, and ophthalmic products. The company's research is connected to alginate-gelatin hydrogels for tissue regeneration applications, indicating a focus on regenerative medicine biomaterials.

Product overview

No product or service information is available from the provided sources. The company website (http://3dglobalbiotech.com.tw/) displays only a verification/loading page with no accessible content. The news sources provided reference unrelated biotechnology companies (YD Bio Limited and Taipei Medical University research) rather than 3D Global Biotech.

Differentiator

Problem solved

Functional benefit

Products and services

• Artificial Bone Grafting Artificial bone grafting material developed for bone regeneration and repair applications, targeted at medical and clinical users in regenerative medicine.
• Biotechnology Inks Biotechnology inks developed by the company for use in biomedical and 3D bioprinting-related applications.
• Ophthalmic Products Ophthalmic products developed by 3D Global Biotech for eye-care and ophthalmology applications.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• CollPlant Biotechnologies: Israel-based developer of recombinant human collagen-based bio-inks and regenerative medicine products, including orthopedics and ophthalmic applications. Directly comparable in biotech inks, bone/soft tissue regeneration, and ophthalmic.
• Organovo Holdings: Pioneer in 3D bioprinting of human tissues for therapeutic and research applications. Direct comparable as a small public bioprinting company pursuing tissue-engineered therapeutic products.
• BICO (CELLINK): Leading bioprinting hardware, biomaterials (including bio-inks), and tissue-engineering consumables provider. Directly comparable in biotech inks and bioprinting systems.

Emerging players

• Aspect Biosystems: Vancouver-based bioprinting company developing tissue-specific therapeutics using microfluidic 3D bioprinting. Comparable in regenerative medicine and bio-ink platform.
• Tissue Regeneration Therapeutics / Tiger Bioactive: Specialty regenerative medicine company focused on bone graft substitutes and bioactive materials. Comparable as a focused emerging player in bone graft substitutes and orthobiologics.
• regenHU: Swiss bioprinting systems manufacturer producing bioprinters and bio-inks for tissue engineering and regenerative medicine research. Directly comparable as a niche bioprinting hardware/bio-ink provider.

Broad incumbents

• Materialise: Global 3D printing services and software company with deep medical segment including patient-specific implants, surgical guides, and dental solutions. Comparable in on-demand medical 3D printing services.
• Stryker (Orthobiologics): Orthopedics and bone graft substitute incumbent (e.g., Vitoss, BIO4) overlapping with 3D Global Biotech's bone grafting vertical.
• Medtronic (Orthobiologics / Bone Graft): Major medtech incumbent with INFUSE bone graft and broader orthobiologics portfolio. Comparable in the artificial bone grafting end-market where 3D Global Biotech competes.
• 3D Systems Healthcare: Major 3D printing incumbent with a dedicated healthcare vertical covering patient-specific implants, surgical planning, and dental/bioprinting-adjacent offerings. Broadly comparable in medical 3D printing hardware and patient-specific implants.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/3dglobalbiotech

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3D Global Biotech